A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Conditions
LGLL - Large Granular Lymphocytic Leukemia · Primary Cutaneous Gamma-Delta T-Cell Lymphoma · Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma · Hepatosplenic T-cell Lymphoma · Subcutaneous Panniculitis-Like T-Cell Lymphoma · Aggressive NK Cell Leukemia · Systemic EBV1 T-cell Lymphoma, if CD8 Positive · Hydroa Vacciniforme-Like Lymphoproliferative Disorder · Extranodal NK/T Cell Lymphoma, Nasal Type · Enteropathy-Associated T-Cell Lymphoma · Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma · Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker) · Cutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Dren Investigational Site, Birmingham, Alabama, United States
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-735-5277Dren Investigational Site, Duarte, California, United States
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site, Irvine, California, United States
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site, Redwood City, California, United States
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-735-5277Dren Investigational Site, New Haven, Connecticut, United States
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site, Tampa, Florida, United States
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site, Boston, Massachusetts, United States
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-735-5277Dren Investigational Site 1, New York, New York, United States
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-735-5277Dren Investigational Site 2, New York, New York, United States
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site, Columbus, Ohio, United States
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-735-5277Dren Investigational Site 2, Pittsburgh, Pennsylvania, United States
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site, Houston, Texas, United States
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site, Charlottesville, Virginia, United States
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-735-5277Dren Investigational Site, Fairfax, Virginia, United States
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site, Seattle, Washington, United States
Contact: Study coordinator (Dren Cntral Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site, Clayton, Victoria, Australia
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site, Richmond, Victoria, Australia
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-735-5277Dren Investigational Site, Nedlands, Washington, Australia
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-735-5277Dren Investigational Site, Pierre-Bénite, France
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site, Rennes, France
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site, Toulouse, France
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site, Berlin, Germany
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site, Cologne, Germany
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site, Leipzig, Germany
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site 1, Hong Kong, Hong Kong, Hong Kong
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site 2, Hong Kong, Hong Kong
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site, Bologna, Italy
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site 1, Busan, South Korea
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site 2, Busan, South Korea
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site, Goyang-si, South Korea
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site 1, Seoul, South Korea
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site 2, Seoul, South Korea
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site 3, Seoul, South Korea
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site, Barcelona, Spain
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site, Salamanca, Spain
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site, Tainan, Taiwan
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277Dren Investigational Site, Taipei, Taiwan
Contact: Study coordinator (Dren Central Contact) · DR-01-ONC-001_inquiries@drenbio.com · 415-737-5277
Study leads
Wan-Jen Hong, MD
Study Director
Dren Bio